MAY 08, 2019 10:30 AM PDT

Discovering Cellular Mechanisms and Biomarkers in Anti-PD1 Non-Responders Using Ingenuity Pathway Analysis Software and OmicSoft OncoLand Datasets from QIAGEN

Sponsored by: QIAGEN
Speaker

Abstract

The last two decades have seen an explosion in the volume of oncology data generated using next-generation sequencing (NGS) and multi-omics techniques. As a result, there is a growing need for computational tools that are powerful enough to generate meaningful hypotheses about the biological mechanisms underlying cancer. In this presentation, we demonstrate how two of QIAGEN’s bioinformatics solutions – Ingenuity Pathway Analysis (IPA) software and the OmicSoft OncoLand database – can be combined to generate testable hypotheses in an immuno-oncology case study (GSE67501). This study sought to understand the mechanism underlying the failure of anti-PD-1 therapy in advanced renal cell carcinoma patients. The study data, along with tens of thousands of other public-domain datasets (including TCGA, SRA, GEO, GTEx and others), have been reprocessed using OmicSoft’s bioinformatics pipeline, and are readily available in OmicSoft’s OncoLand platform. Analysis of these data in OncoLand revealed that UGT1 family members and immune genes were differentially regulated in responder vs non-responder populations, similar to as described in the original publication. These data were then interpreted in IPA, which has millions of findings from peer-reviewed publications. Immunologic, cell cycle, metabolite transport and solute related pathways and functions were found to be enriched. Using IPA’s analytic and predictive capabilities, along with the public data curated from TCGA and GEO and other sources present in OncoLand, we demonstrate how these QIAGEN solutions can be used to generate hypotheses for mechanism of action, and to discover potential therapeutic targets and biomarkers.

Learning Objectives: 

1. Introduction to databases backing Ingenuity Pathway Analysis and Oncoland
2. Studying potential biomarkers and targets through Oncoland’s data mining and comparison tools
3. Generation of peer-reviewed literature backed hypotheses through Ingenuity Pathway Analysis
 


Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
JUN 21, 2022 6:00 AM PDT
JUN 21, 2022 6:00 AM PDT
Date: June 21, 2022 Time: 6:00am (PDT), 9:00am (EDT), 3:00pm (CEST) The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision...
JUN 28, 2022 6:45 AM PDT
JUN 28, 2022 6:45 AM PDT
Date: June 28, 2022 Time: 3:00pm (BST), 4:00pm (CET), 9:00am (CST), 7am (PST) Light-sheet microscopy is an extremely versatile imaging technique with a vast range of implementations that are...
MAR 23, 2022 11:00 AM PDT
MAR 23, 2022 11:00 AM PDT
Date: March 23, 2021 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CEDT) In this presentation, Dr. Middleton will review the development and deployment of large-scale saliva-based COVID-19 test...
MAR 02, 2022 9:00 AM PST
C.E. CREDITS
MAR 02, 2022 9:00 AM PST
Date: March 02, 2022 Time: 9:00am (PST), 12:00pm (EST) Single cell RNA-seq is known to only capture a small fraction of the transcriptome of each cell. Often, this is due to inherent limitat...
APR 28, 2022 8:00 AM PDT
APR 28, 2022 8:00 AM PDT
Date: April 28, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Human pluripotent stem cells (PSCs) and their derivatives hold great potentials in...
MAY 08, 2019 10:30 AM PDT

Discovering Cellular Mechanisms and Biomarkers in Anti-PD1 Non-Responders Using Ingenuity Pathway Analysis Software and OmicSoft OncoLand Datasets from QIAGEN

Sponsored by: QIAGEN


Show Resources
Loading Comments...
Show Resources